DHEA, the brain, and the biology of female sexual desire

Many women describe a specific and confusing change during midlife: they can still enjoy sex once it begins, and may still lubricate or reach orgasm, but they no longer feel the spontaneous pull toward sex that they once did.

This is not necessarily a contradiction. Sexual desire and genital response arise from related—but partially independent—biological systems. These systems can change at different rates during perimenopause and menopause.

DHEA participates in several of these systems. It functions as a neuroactive steroid and as precursor material that tissues can convert into androgens and estrogens. But DHEA is only one part of a larger network involving reward pathways, attention, stress physiology, relationships, medication effects, and genital tissue health.

The work following is based on the Drive–Capacity Model, a peer-reviewed Oxford University Academic publication.

The answer in brief

Sexual desire often declines in midlife because the brain systems that assign erotic importance, the attentional systems that keep erotic cues in awareness, and the genital tissues that produce physical arousal do not change at the same rate.

DHEA may influence both central motivation and local tissue biology. However, a woman’s blood DHEA level does not reliably predict her sexual desire, and research does not show that taking oral DHEA consistently restores libido.

Key points

• Desire can decline while lubrication, sensation, and orgasm remain possible.

• DHEA can act in the nervous system and serve as a precursor for local estrogen and androgen production.

• Low circulating DHEA does not, by itself, diagnose the cause of low desire.

• Oral and locally applied DHEA are biologically different interventions and cannot be assumed to produce the same effects.

• Supporting vulvovaginal comfort may improve sexual experience, but tissue support does not necessarily restore central sexual motivation.

Desire is not controlled by one hormone

The word libido is often used as though it describes a single biological function. In reality, sexual desire emerges from several processes working together:

• the brain must assign value and motivational importance to an erotic cue;

• attention must remain engaged long enough for that cue to develop;

• the genital tissues must be able to respond comfortably;

• the experience must occur within an acceptable emotional, relational, and physical context.

Hormones influence these systems, but they do not operate as simple on-and-off switches.

Large longitudinal studies show that sexual functioning commonly changes across the menopausal transition. Yet the trajectory differs substantially among women and is influenced by physical health, psychological well-being, relationship factors, medication use, stress, sleep, and the personal importance assigned to sexuality.[2]

This is why neither estradiol, testosterone, nor DHEA can fully explain desire on its own.

The Drive–Access–Capacity Model

The Drive–Capacity Model, published in Research Connections by Oxford University Press, proposes that midlife female sexual function can be understood through three interacting systems: Drive, Access, and Capacity.[1]

1. Drive: the motivation to begin

Drive refers to the central brain systems that create erotic motivation, reward anticipation, and the spontaneous emergence of sexual thoughts.

These processes depend partly on mesolimbic reward circuitry: neural pathways that determine whether a stimulus feels important enough to pursue. Dopamine is especially relevant to incentive salience—the process through which the brain assigns motivational value to a cue.

Across midlife, these pathways may become less responsive because of interacting changes in:

• ovarian and adrenal hormone output;

• neurosteroid signaling;

• chronic stress and cortisol activity;

• sleep disruption;

• inflammation;

• medication exposure;

• reward sensitivity and novelty processing.

The result may not be an inability to enjoy sex. Instead, the threshold required to initiate erotic interest may become higher.

A woman may therefore accurately report: “I still like sex when it happens. I just no longer think about starting it.”

2. Access: the ability to enter and remain in an erotic state

Access refers to attentional gating: whether erotic cues can enter awareness and remain stable long enough to activate motivational and physical response systems.

Desire requires more than the biological potential to become aroused. The brain must also be able to hold an erotic thought or sensation in awareness without immediately losing it to competing demands.

Access can be disrupted by:

• cognitive overload;

• caregiving demands;

• work stress;

• sleep fragmentation;

• anxiety or hypervigilance;

• distracting thoughts;

• autonomic dysregulation;

• hormonal volatility affecting attention and cortical signal stability.

This may produce the experience of being unable to “get into it,” even when attraction, affection, and genital responsiveness are still present.

A woman may not have lost all desire potential. She may have difficulty accessing it.

3. Capacity: what the genital tissues can do

Capacity refers to the peripheral physical systems that enable genital response, including:

• lubrication;

• vascular engorgement;

• tissue elasticity;

• mechanical comfort;

• clitoral and vulvar sensation;

• sensory feedback;

• orgasmic response.

These functions depend on epithelial integrity, blood flow, connective tissue structure, sensory nerves, inflammatory state, and local steroid metabolism.

Capacity does not initiate desire. It determines whether the body can translate sexual activation into a comfortable and rewarding physical response.

The Drive–Capacity Gap

Drive and Capacity do not necessarily decline together.

For many women, central sexual motivation begins to change during perimenopause, while physical genital responsiveness remains relatively intact. This creates what the Drive–Capacity Model calls the Drive–Capacity Gap.[1]

A woman may consequently experience:

• little spontaneous interest in sex;

• less erotic imagination;

• fewer urges to initiate;

• difficulty shifting attention toward erotic cues;

while still retaining:

• lubrication after sufficient stimulation;

• clitoral swelling;

• genital sensation;

• pleasure;

• orgasm.

Later, gradual changes in vulvar and vaginal tissue may begin to affect Capacity as well. Dryness, pain, irritation, reduced elasticity, delayed lubrication, or altered sensation can then create an additional physical barrier to sexual engagement.

This timing difference helps explain why the sentence “my libido is gone” can describe several biologically different situations.

Where does DHEA fit?

DHEA, or dehydroepiandrosterone, is an endogenous steroid produced primarily by the adrenal glands. Much of it circulates in its sulfated storage form, DHEAS.

DHEA and DHEAS generally decline across adulthood, although individual trajectories around the menopausal transition are not perfectly linear.

DHEA may be relevant to sexual function through three distinct pathways.

DHEA and central sexual Drive

DHEA is a neuroactive steroid. In experimental models, DHEA and its metabolites interact with signaling systems involved in excitability, inhibition, plasticity, stress response, and reward processing.

These include:

• GABA-A receptor modulation;

• NMDA receptor signaling;

• sigma-1 receptor activity;

• dopaminergic signaling;

• brain-derived neurotrophic factor activity;

• local conversion into estrogens and androgens within neural tissue.

These mechanisms provide a biologically plausible connection between DHEA and motivational Drive.[1]

However, biological plausibility is not the same as demonstrated treatment efficacy. A molecule may participate in a physiological pathway without supplementation reliably correcting every condition associated with that pathway.

DHEA as substrate for local hormone production

DHEA is also precursor material for the local production of active sex steroids.

Depending on the enzymes expressed in a particular tissue, DHEA may enter pathways that produce:

• androstenedione;

• testosterone;

• dihydrotestosterone;

• estrone;

• estradiol.

This process is called intracrine steroidogenesis. Unlike a classical endocrine gland that produces a hormone and releases it into the circulation, an intracrine tissue converts precursor molecules into active hormones within or near the cells that use them.[4]

Vulvar, vestibular, and vaginal tissues express multiple enzymes involved in these conversions, including 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase, aromatase, and 5α-reductase.[1,4]

In simplified form:

DHEAS ↔ DHEA → androgen intermediates → testosterone and DHT

and, where aromatase is expressed:

androgen intermediates → estrogens

The balance of these products depends on the tissue, available enzymes, substrate concentration, age, and physiological state.

DHEA and peripheral sexual Capacity

Locally produced androgens and estrogens may contribute to tissue properties involved in sexual Capacity, including epithelial maintenance, connective tissue architecture, vascular responsiveness, moisture regulation, sensory integrity, and comfort.

Physical comfort can also feed back into motivation.

When sexual activity is associated with dryness, irritation, diminished sensation, or pain, the brain may learn to assign less reward value to the experience. Improving local comfort may remove that inhibitory signal.

But this distinction is essential:

Supporting genital Capacity may make sexual activity more comfortable or rewarding without directly restoring central Drive.

A woman with healthy, comfortable genital tissue may still experience diminished motivation because the primary constraint lies in brain reward processing, attention, stress physiology, medication effects, or relationship context.

Does lower DHEA cause lower libido?

The relationship is not that simple.

In a large community study, researchers measured testosterone, androstenedione, DHEAS, and several domains of female sexual function. No single androgen level reliably predicted low sexual function. Although some statistical associations with very low DHEAS were identified, most women with low DHEAS did not report low sexual function.[3]

This means that a DHEAS blood test may provide information about adrenal androgen physiology, but it cannot independently answer:

• why a woman’s desire has declined;

• whether DHEA is the primary limiting factor;

• whether DHEA treatment will improve sexual function;

• whether the problem lies in Drive, Access, Capacity, or context.

A laboratory value should therefore be interpreted as one element within a larger clinical assessment—not as a direct measurement of libido.

What do DHEA treatment studies show?

The evidence depends strongly on route, dose, population, and outcome measured.

Research question	Evidence	Main finding	What it means
Do blood androgen levels identify women with low desire?	Community study of more than 1,000 women	No single measured androgen reliably predicted low female sexual function.[3]	Blood DHEAS is not a diagnostic libido test.
Does oral DHEA improve low desire after menopause?	Randomized trial of 93 postmenopausal women using 50 mg daily	Oral DHEA did not significantly improve sexual events, sexual function, well-being, or menopause-related quality of life over placebo at 26 weeks. Acne and increased hair growth were more common.[5]	Raising systemic DHEA does not reliably restore desire.
What do systemic DHEA trials show overall?	Meta-analysis of 23 randomized trials involving 1,188 postmenopausal women	No statistically significant overall improvement in libido or sexual function was found; study quality and heterogeneity limited confidence.[6]	Evidence for systemic supplementation remains weak and inconsistent.
Can DHEA influence acute arousal?	Small laboratory studies	Some acute effects on subjective or physiological arousal have been reported, but sample sizes were small and results have not established durable clinical benefit.[9]	Mechanistic signals require confirmation in larger clinical trials.
Does intravaginal prasterone affect sexual function in women with vulvovaginal symptoms?	Randomized trials in postmenopausal women with vulvovaginal atrophy or related symptoms	Improvements were reported in several Female Sexual Function Index domains, including desire, arousal, lubrication, orgasm, satisfaction, and pain.[7,8]	Local treatment may improve sexual function in selected symptomatic populations, but these results do not apply automatically to every woman with low desire.

Why route matters

Oral DHEA, intravaginal prasterone, and an externally applied vulvar formulation are not interchangeable.

They differ in:

• absorption;

• tissue exposure;

• metabolism;

• dose;

• local enzyme environment;

• systemic hormone effects;

• anatomical site;

• intended outcome.

The intravaginal trials studied pharmaceutical prasterone in postmenopausal women selected for vulvovaginal atrophy, dyspareunia, or related genitourinary symptoms.[7,8] Improvements in desire scores may have reflected several interacting effects, including improved comfort, reduced pain, enhanced genital sensation, and local steroid conversion.

Those trials do not establish that oral DHEA treats low desire. They also do not independently establish the effects of every external vulvar formulation.

Each route and formulation requires evidence appropriate to its own delivery system and intended use.

Why desire may improve when physical comfort improves

Sexual desire is not generated only before physical contact. It can also be shaped by anticipated and remembered sensory experience.

If previous sexual activity has involved:

• burning;

• dryness;

• friction;

• pain;

• reduced sensation;

• delayed physical response;

the brain may reasonably assign less reward value to initiating it.

Improving comfort can interrupt this negative feedback loop. A more comfortable and responsive body may make sexual activity easier to approach and more rewarding once it begins.

This is one reason locally directed tissue support may influence broader sexual well-being even when it does not directly act as a central libido treatment.

The reverse is also true: central desire can remain high while local Capacity declines. A woman may want sex but avoid it because her tissue is painful or unresponsive.

Why can I still orgasm if my desire has declined?

Because the systems responsible for motivational initiation and orgasmic Capacity are partially separable.

Orgasm depends on adequate sensory stimulation, peripheral nerve signaling, vascular response, spinal reflex pathways, and central processing. These systems may remain functional even when spontaneous reward anticipation and erotic motivation have diminished.

The ability to orgasm therefore does not prove that desire is unchanged. Nor does reduced desire mean that the genital tissues have lost their capacity for pleasure.

This is the central insight of the Drive–Capacity Gap: wanting and physiological ability can change on different timelines.

Is declining desire inevitable?

No.

Population-level trends do not determine an individual woman’s trajectory. Some women experience little change, some experience a temporary reduction during perimenopause, and others develop persistent low desire that causes significant distress.

For some women, midlife sexuality improves because of greater self-knowledge, reduced pregnancy concerns, changes in relationships, or increased confidence.

Desire may also fluctuate rather than disappear. A woman may experience less spontaneous desire but retain strong responsive desire—interest that emerges after pleasurable or emotionally meaningful engagement has begun.

The relevant question is not whether a woman’s desire matches a cultural expectation. It is whether the change feels acceptable to her or represents a loss she wants to understand.

What else should be considered when desire changes?

A meaningful assessment should consider more than hormone levels.

Relevant factors may include:

• vulvar or vaginal dryness, irritation, or pain;

• sleep disruption;

• depression or anxiety;

• chronic stress;

• relationship safety and satisfaction;

• cognitive overload;

• fatigue;

• antidepressants and other medications;

• thyroid dysfunction;

• prolactin abnormalities;

• surgical menopause;

• cancer treatment;

• chronic illness;

• body-image changes;

• trauma history;

• changes in sensory response;

• personal expectations and distress.

A sudden or marked change deserves particular attention, especially when accompanied by pain, bleeding, neurological symptoms, mood changes, or other new health concerns.

Frequently Asked Questions

What is DHEA?

DHEA, or dehydroepiandrosterone, is an endogenous steroid produced predominantly by the adrenal glands. It circulates as both DHEA and DHEAS and can be converted within certain tissues into androgens and estrogens.

Does DHEA increase libido in women?

Not consistently. DHEA participates in biological pathways relevant to desire and tissue function, but randomized trials of oral DHEA have not shown reliable improvement in low libido. Intravaginal prasterone trials have reported improvements in sexual-function measures in selected postmenopausal women with genitourinary symptoms. These findings are route- and population-specific.

Can a DHEAS blood test explain low libido?

Usually not by itself. No single circulating androgen measurement reliably predicts female sexual function. DHEAS results may be clinically relevant in certain endocrine evaluations, but they should not be interpreted as a direct measure of sexual desire.

Why do I enjoy sex once it starts but rarely want to begin?

Your genital Capacity may still be intact while motivational Drive or attentional Access has changed. This is the pattern described by the Drive–Capacity Gap: reduced initiation or erotic motivation despite preserved physical response and pleasure.

Can dryness lower desire?

Yes. Dryness, irritation, reduced sensation, and pain can make sexual activity less rewarding or create anticipatory avoidance. Addressing tissue comfort may improve the experience, although it may not resolve a separate central Drive or Access problem.

Is low desire always a medical disorder?

No. Desire varies widely among women and across life stages. It becomes a clinical concern when the change is persistent, causes personal distress, or is associated with pain, illness, medication effects, relationship problems, or other symptoms that deserve assessment.

When should I speak with a clinician?

Consider evaluation when desire changes suddenly, causes significant distress, is accompanied by pain or bleeding, follows a medication change, or occurs with fatigue, mood symptoms, endocrine symptoms, or other health changes. A useful assessment should examine Drive, Access, Capacity, medications, general health, and personal context rather than relying on a single hormone measurement.

The central idea

Midlife desire does not decline simply because one hormone “runs out.”

Sexual function emerges from coordination among motivational brain systems, attentional access, genital tissue biology, and lived context. DHEA participates in this network, both as a neuroactive steroid and as substrate for local androgen and estrogen production.

But participation in a pathway does not mean that one DHEA measurement explains desire—or that one form of supplementation will restore it.

For many women, the most useful starting point is to determine what has actually changed:

Is the difficulty wanting, accessing, or physically responding?

That question offers a more biologically accurate path forward than treating libido as a single hormone-dependent function.

---

Written and scientifically reviewed by Laura Kelly, DAOM
Independent researcher and clinician; author of the Drive–Capacity Model of Midlife Female Sexual Function  (Oxford Academic, April 2026)

ORCID 0000-0001-6586-7308

Last scientific review: July 2026

Educational notice: This article provides general scientific information and is not a diagnosis or individualized medical recommendation. DHEA can affect steroid pathways and may be inappropriate in some circumstances. Decisions about systemic or prescription DHEA should be discussed with an appropriately qualified clinician.

Frequently Asked Questions

Why does sexual desire often decline during midlife?

Sexual desire can decline during midlife because several systems involved in sexual function change on different timelines. The brain systems that assign motivational importance to erotic cues, the attentional systems that allow those cues to remain in awareness, and the genital tissues that create physical arousal are related but partly independent.

Changes in ovarian and adrenal hormones, sleep, stress physiology, medications, mood, relationships, cognitive load, and genital comfort may all contribute. Midlife loss of desire therefore cannot usually be attributed to one hormone alone.[1,2]

Why do I enjoy sex once it begins but rarely want to initiate it?

Wanting sex and being physically capable of enjoying it are not the same function.

In the Drive–Access–Capacity Model, Drive refers to the motivation to begin, Access refers to the ability to enter and remain in an erotic state, and Capacity refers to the genital tissues’ ability to respond with sensation, lubrication, swelling, comfort, pleasure, and orgasm.[1]

Drive or Access may decline while Capacity remains relatively preserved. This can produce the experience: “I still enjoy sex once it starts, but I rarely think about initiating it.”

Can I still have orgasms if my libido has declined?

Yes. The neural and physical systems involved in orgasm are partly separable from the systems that generate spontaneous erotic motivation.

Adequate stimulation may still activate genital sensory nerves, vascular responses, spinal reflex pathways, and central orgasmic processing even when the motivational urge to initiate sex has become less frequent. Preserved orgasm does not mean that a change in desire is imaginary or unimportant.[1]

Does lower DHEA cause lower libido?

Not necessarily. DHEA participates in neurosteroid signaling and provides precursor material that some tissues can convert into estrogens and androgens. These pathways make DHEA biologically relevant to sexual function.

However, circulating DHEAS levels do not reliably predict an individual woman’s sexual desire. In population research, no single measured androgen consistently identified women with low sexual function.[3] Low desire should therefore not be diagnosed from a DHEAS result alone.

Does taking DHEA increase libido in women?

Not consistently.

Randomized trials and meta-analyses of oral DHEA have not demonstrated a reliable overall improvement in libido or sexual function among postmenopausal women with otherwise normal adrenal function.[5,6]

Trials of intravaginal prasterone in selected postmenopausal women with vulvovaginal symptoms have reported improvements in several sexual-function measures, including pain, lubrication, arousal, and desire.[7,8] Those findings apply to the particular route, formulation, and symptomatic population studied and should not be generalized automatically to every form of DHEA or every cause of low desire.

Are oral, vaginal, and vulvar DHEA the same?

No. The route and formulation affect where DHEA is delivered, how it is absorbed and metabolized, which tissues are exposed, and the likelihood of systemic hormonal effects.

Oral DHEA enters systemic circulation. Intravaginal prasterone is a pharmaceutical formulation studied inside the vagina in postmenopausal women with specific genitourinary symptoms. An externally applied vulvar formulation is delivered to a different anatomical compartment and requires evidence appropriate to that formulation and intended use.

Results from one route cannot automatically establish the effects of another.

Can vaginal or vulvar dryness lower sexual desire?

Yes. Dryness, burning, friction, pain, irritation, or diminished sensation can make sexual activity less rewarding and may create anticipatory avoidance.

The brain uses previous experience to predict whether an activity is likely to feel rewarding or unpleasant. If sexual contact has repeatedly caused discomfort, the motivational value assigned to initiating it may decrease.

Improving tissue comfort may therefore improve sexual experience and remove one inhibitory influence on desire. It may not, however, correct a separate problem involving central Drive, attentional Access, medication effects, stress, or relationship context.

Is responsive desire normal?

Yes. Desire does not always appear spontaneously before sexual activity.

For some women, especially during midlife, interest emerges responsively after affectionate, sensory, emotionally meaningful, or erotic engagement has begun. A shift from spontaneous to responsive desire is not automatically a disorder.

The clinically relevant question is whether the change feels acceptable to the woman or represents a persistent and distressing loss.

Can a blood hormone test explain why my desire has changed?

Usually not by itself. Estradiol, testosterone, DHEA, DHEAS, thyroid markers, and prolactin may be relevant in selected clinical circumstances, but no single blood measurement functions as a direct test of female libido.

A meaningful assessment should consider motivation, attention, genital comfort and response, medications, sleep, mood, stress, endocrine health, chronic illness, relationship context, and the timing and severity of the change.

Is low sexual desire always a medical disorder?

No. Sexual desire varies substantially between women and across life stages. A woman does not have a disorder merely because her level of interest differs from someone else’s or from a cultural expectation.

A change becomes clinically important when it is persistent, causes personal distress, is associated with pain or other symptoms, or may reflect medication effects, illness, endocrine change, or another treatable factor.

When should I speak with a clinician?

Consider clinical evaluation when a change in desire:

• occurs suddenly or is unusually marked;

• causes significant personal distress;

• is accompanied by vulvar or vaginal pain, bleeding, skin changes, or reduced sensation;

• follows a new medication or dose change;

• occurs with substantial fatigue, mood change, neurological symptoms, or endocrine symptoms;

• follows cancer treatment, pelvic surgery, or surgical menopause.

An appropriate assessment should examine the interacting contributions of Drive, Access, Capacity, general health, medications, and lived context rather than relying on one hormone measurement.

 

By Laura Kelly, DAOM, L.Ac., Dipl. O.M.  A California-licensed primary care provider and nationally board-certified clinician with a clinical focus on women’s health and healthy aging. Research Scholar, Ronin Institute. ORCID: 0000-0001-6586-7308.  More about Dr. Kelly

References

1. Kelly L. The drive–capacity model: a systems biology framework for midlife female sexual function. Research Connections. 2026;1(2):vmag023. doi: 10.1093/rescon/vmag023.

2. Avis NE, Colvin A, Karlamangla AS, et al. Change in sexual functioning over the menopausal transition: results from the Study of Women’s Health Across the Nation. Menopause. 2017;24(4):379–390. doi: 10.1097/GME.0000000000000770. PMID: 27801705.

3. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294(1):91–96. doi: 10.1001/jama.294.1.91. PMID: 15998895.

4. Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019;26(2):220–224. doi: 10.1097/GME.0000000000001177. PMID: 30130283.

5. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The Journal of Sexual Medicine. 2009;6(9):2579–2590. doi: 10.1111/j.1743-6109.2009.01381.x. PMID: 19619146. 

6. Elraiyah T, Sonbol MB, Wang Z, et al. The benefits and harms of systemic dehydroepiandrosterone in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2014;99(10):3536–3542. doi: 10.1210/jc.2014-2261. PMID: 25279571.

7. Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16(5):923–931. doi: 10.1097/GME.0b013e31819e85c6. PMID: 19424093.

8. Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. The Journal of Sexual Medicine. 2015;12(12):2401–2412. doi: 10.1111/jsm.13045. PMID: 26597311.

9. Hackbert L, Heiman JR. Acute dehydroepiandrosterone effects on sexual arousal in postmenopausal women. Journal of Women’s Health & Gender-Based Medicine. 2002;11(2):155–162. doi: 10.1089/152460902753645290. PMID: 11975863.